ESPE Yearbook of Paediatric Endocrinology

ESPE Yearbook of Paediatric Endocrinology

ISSN 1662-4009 (online)

Published by BioScientifica

Page 1 of about 1 results

ey0017.3-5 | Follow-up paper - Graves disease | ESPEYB17

3.5. Teprotumumab for the treatment of active thyroid eye disease

RS Douglas , GJ Kahaly , A Patel , S Sile , EHZ Thompson , R Perdok , JC Fleming , BT Fowler , C Marcocci , M Marino , A Antonelli , R Dailey , GJ Harris , A Eckstein , J Schiffman , R Tang , C Nelson , M Salvi , S Wester , JW Sherman , T Vescio , RJ Holt , TJ Smith

To read the full abstract: N Engl J Med. 2020;382:341–352.Teprotumumab, an IGF-1R monoclonal antibody, showed promising results for the treatment of Graves’ orbitopathy in a first phase 2 study reported in 2017 [1]. Here, this randomized double-masked, placebo controlled phase 3 multicenter study confirms those initial promising results in patients with moderate-to severe Graves’ eye disease: The primary outcome of proptosis reduc...
0 shares

Published by BioScientifica

ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more